(Q35805639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Vascular-targeting therapies for treatment of malignant disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Dietmar W Siemann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

David J Chaplin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

2491-2499

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Targeting tumor blood vessels: an adjuvant strategy for radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Vascular attack as a therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Vascular occlusion and tumour cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Expression of endoglin (CD105) in tumor blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

DMXAA: an antivascular agent with multiple host responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Combination of vascular targeting agents with thermal or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20299

7 January 2021

Identifiers

DOI

10.1002/CNCR.20299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15197790%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference